Incidence and time trends of childhood hematological neoplasms: a 36-year population-based study in the southern European context, 1983-2018.
childhood
hematological neoplasms
incidence
incidence trends
leukemia-lymphoma
population-based registries
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
03
2023
accepted:
07
07
2023
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Hematological neoplasms (HNs) are the first and most common childhood cancers globally. Currently, there is a lack of updated population-based data on the incidence of these cancers in the Spanish pediatric population. This study aimed to describe the incidence and incidence trends of HNs in children (0-14 years) in Spain using data from the Spanish Network of Cancer Registries and to compare the results with other southern European countries. Data were extracted from 15 Spanish population-based cancer registries between 1983 and 2018. Cases were coded according to the A total of 4,747 HNs were recorded (59.5% boys). Age distribution [n (%)] was as follows: <1 year, 266 (5.6%); 1-4 years, 1,726 (36.4%); 5-9 years, 1,442 (30.4%); and 10-14 years, 1,313 (27.6%). Leukemias were the most common group, with a CR and an ASR Leukemias are the most common HNs in children, and their incidence has remained stable since 1988, whereas the incidence of lymphomas has increased every year. Lymphoma incidence is like that of other southern European countries, while leukemia incidence is similar only to that of southwestern European countries. Collaborative cancer registry projects allow for assessing epidemiological indicators for cancers such as HNs, which helps health authorities and clinicians provide more knowledge about these malignancies.
Sections du résumé
Background
UNASSIGNED
Hematological neoplasms (HNs) are the first and most common childhood cancers globally. Currently, there is a lack of updated population-based data on the incidence of these cancers in the Spanish pediatric population. This study aimed to describe the incidence and incidence trends of HNs in children (0-14 years) in Spain using data from the Spanish Network of Cancer Registries and to compare the results with other southern European countries.
Methods
UNASSIGNED
Data were extracted from 15 Spanish population-based cancer registries between 1983 and 2018. Cases were coded according to the
Results
UNASSIGNED
A total of 4,747 HNs were recorded (59.5% boys). Age distribution [n (%)] was as follows: <1 year, 266 (5.6%); 1-4 years, 1,726 (36.4%); 5-9 years, 1,442 (30.4%); and 10-14 years, 1,313 (27.6%). Leukemias were the most common group, with a CR and an ASR
Conclusion
UNASSIGNED
Leukemias are the most common HNs in children, and their incidence has remained stable since 1988, whereas the incidence of lymphomas has increased every year. Lymphoma incidence is like that of other southern European countries, while leukemia incidence is similar only to that of southwestern European countries. Collaborative cancer registry projects allow for assessing epidemiological indicators for cancers such as HNs, which helps health authorities and clinicians provide more knowledge about these malignancies.
Identifiants
pubmed: 37560466
doi: 10.3389/fonc.2023.1197850
pmc: PMC10408119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1197850Informations de copyright
Copyright © 2023 Trallero, Sanvisens, Almela Vich, Jeghalef El Karoni, Saez Lloret, Díaz-del-Campo, Marcos-Navarro, Aizpurua Atxega, Sancho Uriarte, De-la-Cruz Ortega, Sánchez, Perucha, Franch, Chirlaque, Guevara, Ameijide, Galceran, Ramírez, Camblor, Alemán, Gutiérrez, Marcos-Gragera and REDECAN.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pediatr Blood Cancer. 2004 Dec;43(7):749-57
pubmed: 15390289
Eur J Cancer Prev. 2010 May;19(3):173-81
pubmed: 20361423
Paediatr Perinat Epidemiol. 1990 Jul;4(3):303-24
pubmed: 2374749
Lancet Oncol. 2017 Jun;18(6):719-731
pubmed: 28410997
Cancer Treat Rev. 2010 Jun;36(4):277-85
pubmed: 20231056
Maturitas. 2018 May;111:A1-A2
pubmed: 29395455
Eur J Cancer. 2006 Sep;42(13):1952-60
pubmed: 16919763
Ann Oncol. 2010 May;21 Suppl 3:iii103-110
pubmed: 20427353
Mol Biol Rep. 2021 Jan;48(1):817-822
pubmed: 33438082
Front Public Health. 2021 Dec 24;9:805757
pubmed: 35004601
Eur J Cancer Prev. 2010 Jul;19(4):247-55
pubmed: 20395866
Cancer Epidemiol. 2018 Oct;56:21-30
pubmed: 30025251
Cancer Epidemiol. 2019 Aug;61:157-164
pubmed: 31279990
Radiol Clin North Am. 2008 Mar;46(2):175-98, vii
pubmed: 18619375
Cancer Med. 2021 Jul;10(13):4575-4586
pubmed: 34076339
Med J Aust. 2020 Feb;212(3):113-120
pubmed: 31876953
Cancer. 2005 Apr 1;103(7):1457-67
pubmed: 15712273
Ann Oncol. 2010 May;21 Suppl 3:iii3-13
pubmed: 20427357
Leukemia. 2002 Apr;16(4):720-5
pubmed: 11960355
Clin Transl Oncol. 2017 Mar;19(3):301-316
pubmed: 27447899
Am J Epidemiol. 2019 Jun 1;188(6):1130-1135
pubmed: 30834440
Cancer Sci. 2018 Feb;109(2):422-434
pubmed: 29178401
PLoS One. 2017 Jul 24;12(7):e0181805
pubmed: 28742150
Clin Transl Oncol. 2018 Oct;20(10):1289-1301
pubmed: 29623582
Medicine (Baltimore). 2018 Oct;97(41):e12797
pubmed: 30313108
Stat Med. 2003 Oct 15;22(19):3055-71
pubmed: 12973787
Cancer Causes Control. 2013 Jun;24(6):1111-8
pubmed: 23529470
Cancer Epidemiol. 2022 Oct;80:102239
pubmed: 35994888
Hematol Oncol Clin North Am. 2010 Feb;24(1):35-63
pubmed: 20113895
Lancet Oncol. 2018 Sep;19(9):1159-1169
pubmed: 30098952
Front Genet. 2012 Nov 28;3:268
pubmed: 23226157
Acta Oncol. 2020 May;59(5):588-595
pubmed: 32048526
Am Fam Physician. 2014 May 1;89(9):731-8
pubmed: 24784336
Am J Hematol. 2023 Jan;98(1):23-30
pubmed: 36178436
Cancer Epidemiol. 2021 Aug;73:101968
pubmed: 34174725